These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 16203879

  • 1. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Colwell CW, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW, EXULT B Study Group.
    J Bone Joint Surg Am; 2005 Oct; 87(10):2169-77. PubMed ID: 16203879
    [Abstract] [Full Text] [Related]

  • 2. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 3. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW.
    Ann Intern Med; 2002 Oct 15; 137(8):648-55. PubMed ID: 12379064
    [Abstract] [Full Text] [Related]

  • 4. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, THRIVE Treatment Study Investigators.
    JAMA; 2005 Feb 09; 293(6):681-9. PubMed ID: 15701909
    [Abstract] [Full Text] [Related]

  • 5. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug 09; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 6. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, METHRO III Study Group.
    Thromb Haemost; 2003 Feb 09; 89(2):288-96. PubMed ID: 12574809
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B.
    Drugs; 2004 Feb 09; 64 Suppl 1():27-35. PubMed ID: 15586625
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, AstraZeneca Arthroplasty Study Group.
    Arch Intern Med; 2001 Oct 08; 161(18):2215-21. PubMed ID: 11575978
    [Abstract] [Full Text] [Related]

  • 9. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner GA, Whitsett TL, O'Connell MB, Ohar JA, Young TR, Enoxaparin Clinical Trial Group.
    J Bone Joint Surg Am; 2001 Jun 08; 83(6):900-6. PubMed ID: 11407799
    [Abstract] [Full Text] [Related]

  • 10. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Jun 08; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 11. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb 08; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 12. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 13. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Lotke PA, Callaghan JJ, Dorr LD, Engh GH, Hanssen AD, Healy WL, Lachiewicz PF, Lonner JH, Nelson C, Ranawat CS, Ritter MA, Salvati EA, Sculco TP, Thornhill TS.
    J Bone Joint Surg Am; 2006 May 30; 88(5):1163; author reply 1163-5. PubMed ID: 16651602
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
    Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW.
    J Thromb Haemost; 2003 Oct 30; 1(10):2119-30. PubMed ID: 14521593
    [Abstract] [Full Text] [Related]

  • 15. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV, Bounameaux H.
    Semin Vasc Med; 2005 Aug 30; 5(3):276-84. PubMed ID: 16123915
    [Abstract] [Full Text] [Related]

  • 16. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D, Melagatran for Thrombin inhibition in Orthopaedic surgery.
    Lancet; 2002 Nov 09; 360(9344):1441-7. PubMed ID: 12433510
    [Abstract] [Full Text] [Related]

  • 17. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A, EXPRESS Study Group.
    J Thromb Haemost; 2003 Dec 09; 1(12):2490-6. PubMed ID: 14675083
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
    Mouret P.
    Hamostaseologie; 2002 Aug 09; 22(3):21-4. PubMed ID: 12215757
    [Abstract] [Full Text] [Related]

  • 20. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul 09; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.